A human umbilical cord stem cell rescue therapy in a murine model of toxic liver injury

Campli, C. Di; Piscaglia, A.C.; Pierelli, Luca; Rutella, Sergio; Bonanno, Giuseppina; Alison, Malcolm R.; Mariotti, Andrea; Vecchio, Fabio Maria; Nestola, Manuela; Monego, Giovanni; Michetti, Fabrizio; Mancuso, Stefano; Pola, Paolo; Leone, Giuseppe; Gasbarrini, Giovanni; Gasbarrini, Antonio

doi:10.1016/j.dld.2004.03.017

Cited by 74 publications

(46 citation statements)

References 62 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although HSCs do not likely differentiate into authentic cardiomyocytes (41,42), BM-derived cells that retain hematopoietic markers have been found in the heart and likely mediate improved myocyte function through paracrine effects (43). Similarly, intraperitoneal delivery of HSCs/HPCs reduces alcohol-induced liver damage and improves survival in immunodeficient mice (44), and infusion of G-CSF-primed hematopoietic stem cells accelerates regeneration and improves survival after liver injury or liver transplant (45,46). Although the clinical improvements in these preclinical and clinical studies have generally been modest, increasing the homing efficiency of the HSCs/HPCs to the injured or ischemic tissue might well lead to more robust results.…”

Section: Discussionmentioning

confidence: 99%

CCR2 mediates hematopoietic stem and progenitor cell trafficking to sites of inflammation in mice

Si¹,

Tsou²,

Croft³

et al. 2010

J. Clin. Invest.

168

155

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

CCR2 mediates hematopoietic stem and progenitor cell trafficking to sites of inflammation in mice

Si¹,

Tsou²,

Croft³

et al. 2010

J. Clin. Invest.

168

155

View full text Add to dashboard Cite

“…These cell types can become an important area to study in medicine allowing for potentially new treatment options for additional diseases or conditions [45] including brain injury [46][47][48], strokes [47,[49][50][51]], Parkinson's [52], Alzheimer's [50,53], Huntington's [54] and amyotrophic lateral sclerosis [50,55]. Other diseases in early stages of investigation include liver disorders [56], diabetes [57,58], and myocardial infarction [49,59]. Therapeutic targets for stem cells from cord blood include orthopedic applications for cartilage repair, spinal fusion and regenerative medicine [27,44,60,61].…”

Section: Cord Blood Derived Stem Cells and Regenerative Medicinementioning

confidence: 99%

Umbilical cord blood banking: an update

Butler

Menitove²

2011

J Assist Reprod Genet

View full text Add to dashboard Cite

Background Umbilical cord blood is a potential vast source of primitive hematopoietic stem and progenitor cells available for clinical application to reconstitute the hematopoietic system and/or restore immunological function in affected individuals requiring treatment. Cord blood can be used as an alternative source for bone marrow transplantation and its use is developing into a new field of treatment for pediatric and adult patients presenting with hematological disorders, immunological defects and specific genetic diseases. Discussion More than 25,000 allogeneic cord blood transplantations have been performed worldwide since the first cord blood transplantation in 1988. There are two banking options for storing umbilical cord blood [private (family) and public]. Cord blood stored in private banks are used for either autologous or allogeneic transplants for the infant donor or related family members but private cord blood banks are not searchable or available to the public. More than 780,000 cord blood units are stored in over 130 private cord blood banks, worldwide, and over 400,000 units in more than 100 quality controlled public cord blood banks.Conclusions Researchers continue to evaluate the usefulness of cord blood cells in treating human diseases or disorders for purposes other than hematological disorders including heart disease, strokes, brain or spinal cord injuries and cancer. This review summarizes the status of umbilical cord blood banking, its history and current and potential use in the treatment of human disease.

show abstract

“…BM is rich source of SCs that are relatively easily accessible by aspiration of bone marrow cavities and over the past decade several investigators demonstrated that BM-derived cells can contribute to the regeneration of various organs and tissues (Di Campli et al, 2004;Lagasse et al, 2000;Orlic et al, 2001). These observations were mainly explained by the hypothesis that BM-derived HSCs are "plastic" and thus could trans-dedifferentiate into SCs committed for various non-hematopoietic organs and tissues (Mezey et al, 2000).…”

Section: Bm-derived Stem Cells and Their Potential Role In Regeneratimentioning

confidence: 99%

Very small embryonic-like (VSEL) stem cells in adult organs and their potential role in rejuvenation of tissues and longevity

Ratajczak

Zuba‐Surma

Shin

et al. 2008

Experimental Gerontology

View full text Add to dashboard Cite

Recently, we purified rare CXC chemokine receptor 4 expressing (CXCR4 + ) small stem cells (SCs) from the murine bone marrow (BM) that express markers characteristic for embryonic (E)SCs, epiblast (EP)SCs, and primordial germ cells (PGCs). We named these primitive cells very small embryonic-like (VSEL) SCs (VSELs). Our data indicate that VSELs are also present in many other organs in mice and that they may differentiate into cells from all three germ layers. Similar SCs were also isolated from human cord blood (CB) and mobilized peripheral blood (mPB). We hypothesize that VSELs are deposited during gastrulation and organogenesis in developing organs/tissues of mammals as a population of pluripotent stem cells (PSCs) that give rise to tissue committed monopotent SCs and that their number decreases with age. Therefore VSELs could play a pivotal role in normal rejuvenation of adult tissues as well as involvement in regeneration of damaged organs. Thus, these cells are potential SCs candidates for regenerative medicine and we envision that the regenerative potential of these cells could be harnessed to decelerate the aging processes.

show abstract

A human umbilical cord stem cell rescue therapy in a murine model of toxic liver injury

Cited by 74 publications

References 62 publications

CCR2 mediates hematopoietic stem and progenitor cell trafficking to sites of inflammation in mice

CCR2 mediates hematopoietic stem and progenitor cell trafficking to sites of inflammation in mice

Umbilical cord blood banking: an update

Very small embryonic-like (VSEL) stem cells in adult organs and their potential role in rejuvenation of tissues and longevity

Contact Info

Product

Resources

About